Phase II - development of a prophylactic onchocerciasis vaccine
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93019C00028
- Awardee
-
PAI Life Sciences Inc. UEI MSMLUCM9DRT6
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,338,680
Award facts
- Contract value 100% obligated
- $2,338,680.13 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 5 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Seattle, WA 98102, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | -$623,005 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $2,961,685 |
About this award
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to PAI Life Sciences Inc., a self-certified small disadvantaged business. The $2,338,680.13 definitive contract is for the Phase II development of a prophylactic onchocerciasis (river blindness) vaccine under the SBIR program. The contract is a cost plus fixed fee arrangement with a completion date of May 15, 2024. PAI Life Sciences is collaborating with Thomas Jefferson University and New York Blood Center, Inc. as subcontractors to conduct efficacy studies, develop potency assays, and assess safety and immunogenicity in non-human primates. This contract award is designated as a total small business set-aside, supporting NIAID's efforts to advance the development of preventative vaccines for neglected tropical diseases.
Quick answers
Who was awarded contract 75N93019C00028?
75N93019C00028 was awarded to PAI Life Sciences Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 16, 2019.
How much is contract 75N93019C00028 worth?
The government has obligated $2,338,680 on 75N93019C00028.
Was contract 75N93019C00028 competed?
The extent of competition for 75N93019C00028 was full and open competition after exclusion of sources. The government received 5 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award